TTBB CAS 124750-51-2 Puritas >96.0% (HPLC)
Ruifu Chemical Supple Irbesartan intermedia:
Irbesartan CAS 138402-116
Cyano-Irbesartan CAS 138401-24-8
Trityl Irbesartan CAS 138402-10-5
TTBB CAS 124750-51-2
Irbesartan Side Catena Hydrochloridis CAS 151257-01-1
Nomen chemicum | 5-(4'-Bromomethyl-1,1'-Biphenyl-2-yl)-1-Triphenylmethyl-1H-Tetrazole |
Synonyma | TTBB;BBTT;5-[4'-Bromomethyl-(1,1'-Biphenyl)-2-yl]-1-Triphenylmethyltetrazole;N-(Triphenylmethyl) -5-(4'-Bromomethylbiphenyl-2-yl-)tetrazole;Olmesartan Impurity 12;Losartan Bromo N1-Trityl immunditia |
CAS Number | 124750-51-2 |
CATTUS Number | RF-PI1878 |
Stock Status | In Stock, Productio Capacitas 150MT/Annus |
Formulae hypotheticae | C33H25BrN4 |
M. Pondus | 557.48 |
Liquescens punctum | 152.0~155.0℃ |
Density | 1.28±0.10 g/cm3 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba ad fere album pulveris |
Puritas / Analysis Methodus | >96.0% (HPLC) |
Damnum in Siccatio | <0.50% |
immunditiam A | <2.00% (HPLC) 5-(4-Methyl-1,1-Biphenyl-2-yl)-1-Triphenylmethyl-1H-Tetrazole |
impudicitia B | <2.00% 5-(4'.4'-Dibromomethyl-1,1-Biphenyl-2-yl)-1-Triphenylmethyl-1H-Tetrazole |
Infrared Imaginis | Conformat ut Structure |
Test Standard | Enterprise Standard |
Consuetudinem | MEDIUS IRBESARTAN (CAS: 138402-11-6).Olmesartan Medoxomil Impuritas |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
5-(4'-Bromomethyl-1,1'-Biphenyl-2-yl)-1-Triphenylmethyl-1H-Tetrazole (TTBB) (CAS: 124750-51-2) medium est Irbesartan (CAS: 138402-11 -6).Irbesartan adhibetur pro curatione hypertensionis, et nephropathia diabetica cum serum elevatum creatinine et proteinuria (>300 mg/die) in aegris cum diabete speciei et hypertensione.Irbesartan etiam pro secundo agente in curatione conges.Irbesartan est angiotensin II receptor antagonista maxime adhibita ad hypertensionem curationem.Sanofi Investigatio evoluta est (nunc Sanofi-Aventis pars).Communiter venales sunt a Sanofi-Aventis et Bristol-Myers Squibb sub nominibus commercii Aprovel, Karvea et Avapro.